Lancet

AstraZeneca's investigational GLP-1 pill, elecoglipron, demonstrated significant weight loss in a Phase 2 obesity trial (11.2% after 36 weeks) and improved blood sugar control in a diabetes trial (1.74 percentage-point A1C reduction). Results were compared to oral Ozempic, which showed a smaller A1C decrease in the same study.

Eli Lilly's next-generation obesity drug, retatrutide, demonstrated significant weight loss and blood sugar reduction in a study, but new data revealed seven cases of arrhythmias and three major cardiovascular complications among 403 participants. The findings were presented at the American Diabetes Association meeting and published in the Lancet.

Fraudulent citations are becoming more common in research papers, with a growing number leading to dead ends and fabricated references. A new study published in the Lancet blames tools using generative AI for the issue. The problem is polluting the public record of science.